DOTmed January 14, 2025
Lantheus Holdings, Inc., based in Bedford, Massachusetts, has announced plans to acquire Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd., for $350 million upfront, and up to $400 million in additional earn-out and milestone payments.
Life Molecular brings Neuraceq, an F-18 PET imaging agent approved for detecting beta-amyloid plaques in patients being evaluated for Alzheimer’s disease or other cognitive impairments.
“This acquisition aligns with our strategy to drive long-term growth and value creation by investing in high-potential, complementary assets and R&D capabilities,” said Lantheus CEO Brian Markison. “We are excited to combine resources and expertise to deliver a meaningful impact for patients and clinicians worldwide.”
The deal includes Life Molecular’s established R&D capabilities, manufacturing infrastructure, and...
Today's Sponsors
Today's Sponsor